In findings from a phase 2a trial that were presented at the American Diabetes Association Scientific Sessions and simultaneously published in The Lancet , 71% of adults receiving coadministered cagrilintide and semaglutide 2.4 mg, dubbed CagriSema (Novo Nordisk), lost at least 10% of their body weight, and 89% of adults achieved an HbA1c of less than 7% with the combination therapy
Furthermore, the BHBA-induced decrease of H2AK119ub was dependent on L-type VSCCs, while the increase of H3K4me3 mainly resulted from BHBA-activated cAMP/PKA signaling (Figure 6)
The organoid-derived proteins AT, A1AT and FVII were N-glycosylated, compatible with 4, 4 and 2 mature N-glycans, respectively, and similar to those found in the plasma of healthy adults
This guide compares all three delivery methods so you can make an informed decision with your physician